Gujarat Themis Biosyn Limited has informed the Exchange about change in Management
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited financial results for Q4 and full year ended March 31, 2025. Full-year revenue declined to about Rs. 153.23 crore from Rs. 174.19 crore last year, while net profit fell to Rs. 48.77 crore from Rs. 59.16 crore. Q4 net profit came in at Rs. 12.00 crore versus Rs. 15.89 crore in the year-ago quarter. The board recommended a final dividend of Rs. 0.67 per share (67% on face value of Re. 1), totalling around Rs. 7.30 crore, subject to shareholder approval. The board also appointed KRS AND Co. as the new Secretarial Auditor for five years (FY26–FY30) and re-appointed Raja Dutta & Co. as Cost Auditor for FY26. The statutory auditor issued an unmodified (clean) opinion on the results.
Mixed signals for shareholders: revenue and profits are down year-on-year, but the dividend has been maintained and a clean audit opinion was issued. Investors should note the earlier-approved merger with Themis Medicare Limited (swap ratio 118:100) is still pending NCLT and regulatory approvals, and a large capital work-in-progress build-up (nearly doubled to Rs. 184 crore) signals ongoing expansion.